in Appreciably Shorter Time and at Lower Costs
Demonstrates Superiority Compared to Standard of Care in Prospective, Randomized Controlled Trial
PRINCETON, N.J.–(BUSINESS WIRE)–The Geistlich Medical business unit of Geistlich Pharma AG, a family owned, Swiss-based global leader in regenerative solutions, is proud to announce the results from their clinical study of the Geistlich Derma-Gide® Advanced Wound Matrix. The study, “Use of a Purified Reconstituted Bilayer Matrix (PRBM) in the Management of Chronic Diabetic Foot Ulcers Improves Patient Outcomes vs Standard of Care – Results of a Prospective Randomized Controlled Multi-Center Clinical Trial,” was peer-reviewed and published in the International Wound Journal – Wiley Online Library … The paper was authored by David G. Armstrong, DPM, MD, PhD; Dennis P. Orgill, MD, PhD; Robert D. Galiano, MD; Paul M. Glat, MD; Jarrod P. Kaufman, MD; Marissa J. Carter, MA, PhD; Lawrence A. DiDomenico, DPM; and Charles M. Zelen, DPM, FACFAS. The paper is now available in the Wiley Online Library at https://onlinelibrary.wiley.com/doi/full/10.1111/iwj.13715 … In a 40-patient, prospective, randomized, controlled multicenter clinical trial comparing a purified reconstituted bilayer matrix (PRBM, Geistlich Derma-Gide) vs. Standard of Care (SOC – collagen alginate dressing), Geistlich Derma-Gide was found to be superior relative to healing rates and time to wound closure … read more